The acute respiratory distress syndrome therapeutics pipeline is expected to witness nominal growth in the coming year due to the slow research and development activities of the pipeline drugs. Some of the factors driving the growth of the pipeline include approval of new therapies that include but are not limited to, tissue factor antagonists, cluster of differentiation modulators, p38 kinase inhibitors and DNA polymerase inhibitors. Also, increasing awareness regarding the acute respiratory distress syndrome treatment, high demand for safe and effective medications and technological advancements are also supporting the growth of the acute respiratory distress syndrome therapeutics pipeline.
According to American Lung Association, acute respiratory distress syndrome is a rapidly progressive disease occurring in critically ill patients. The main complication in acute respiratory distress syndrome is the leakage of fluid into the lungs that leads to difficulty in breathing. Acute respiratory distress syndrome, is a buildup of fluid in the tiny air sacs in the lungs called alveoli, resulting in less oxygen to the organs, which is very dangerous. Acute respiratory distress syndrome occurs when there is significant trauma that either affects the lungs directly or indirectly. Some of the traumas associated with the disease are sepsis (a blood infection), severe pneumonia, major trauma and shock from any cause. The body responds to this trauma with an inflammatory reaction that releases numerous natural molecules into the bloodstream. Normally, this inflammatory reaction would be protective and helps in fighting infections or healing of injuries. However, in some people, these inflammatory molecules are responsible for the leakage of fluid from the small blood vessels into lungs. Fluid leaves these small vessels and goes into the alveoli. The alveoli filled with this fluid, makes obstruction difficult for oxygen to get into the bloodstream.
Faron Pharmaceuticals Ltd. is developing a recombinant human interferon beta-1a therapeutic candidate for the prevention of the disease. A phase III clinical trial is going on in Finland, Spain and Germany. Recombinant human interferon beta-1a got orphan drug designation by the European Medicines Agency for the treatment of acute respiratory distress syndrome.
Various pharmaceutical companies are collaborating for the development of the drug candidates to treat acute respiratory distress syndrome. In June 2016, Faron Pharmaceuticals Ltd. entered into a licensing agreement with Pharmbio Korea, for the development and commercialization of interferon beta-1a in Korea, for the treatment of acute respiratory distress syndrome. Under the agreement terms, Faron received an initial signing fee of €750 000, and was entitled to receive additional, undisclosed development based milestones.
The use of off-label drugs such as Nimbex, Levaquin and other generics such as methylprednisolone, clindamycin and lorazepam for acute respiratory distress syndrome are dominating the pipeline. However, complex mechanism of action of the disease and low incidence of the disease associated with the treatment act as key barriers for growth of the pipeline.
Some of the companies having a pipeline of acute respiratory distress syndrome therapeutics include GlaxoSmithKline plc, Altor BioScience Corporation, Pfizer, Inc., BioLineRx, AbbVie, Inc., Amgen, Alliance Pharmaceutical Corporation, Daiichi Sankyo Co., Ltd. and Faron Pharmaceuticals Ltd.